Serum sickness, encephalitis and other complications of anti-cytokine therapy

Best Practice and Research: Clinical Gastroenterology

Volumn 23, Issue 1, 2009, Pages 101-112

  Vermeire, Séverine ^a   Van Assche, Gert ^a   Rutgeerts, Paul ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

adalimumab; anti TNF therapy; certolizumab pegol; immunogenicity; infliximab; natalizumab; progressive multifocal leucoencephalopathy; safety

Indexed keywords

ADALIMUMAB; ADRENALIN; AZATHIOPRINE; BETA1A INTERFERON; CERTOLIZUMAB PEGOL; CORTICOSTEROID; HYDROCORTISONE; IMMUNOGLOBULIN E; INFLIXIMAB; MERCAPTOPURINE; NATALIZUMAB; PLACEBO; PROMETHAZINE;

ANTIBODY PRODUCTION; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CROHN DISEASE; DEMYELINATING DISEASE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG FATALITY; DRUG INDICATION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENCEPHALITIS; HEART FAILURE; HUMAN; IMMUNOGENICITY; LEUKOENCEPHALOPATHY; LUPUS VULGARIS; LYMPHOMA; MULTIPLE SCLEROSIS; OPTIC NEURITIS; PATIENT MONITORING; REMISSION; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; SEIZURE; SERUM SICKNESS; SIDE EFFECT; TUBERCULOSIS; ULCERATIVE COLITIS;

ANTI-INFLAMMATORY AGENTS; ANTIBODY FORMATION; BIOLOGICAL PRODUCTS; CYTOKINES; DRUG HYPERSENSITIVITY; GASTROINTESTINAL AGENTS; HUMANS; INFLAMMATORY BOWEL DISEASES; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; PATIENT SELECTION; RISK ASSESSMENT; SERUM SICKNESS;

EID: 60949093912     PISSN: 15216918     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bpg.2008.12.005     Document Type: Article

References (53)

1. Travis S.P., Stange E.F., Lémann M., et al. European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut 55 Suppl 1 (2006 Mar) i16-i35
2. Travis S.P., Stange E.F., Lémann M., et al. European evidence based consensus on the management of ulcerative colitis: current management. J Crohn's Colitis 2 (2008) 24-63
3. Breese E., Michie C., Nicholls S., et al. Tumor necrosis factor alpha-producing cells in the intestinal mucosa of children with inflammatory bowel disease. Gastroenterology 106 (1994) 1455-1466
4. Reinecker H.C., Steffen M., Witthoeft T., et al. Enhanced secretion of tumour necrosis factor-alpha IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease. Clin Exp Immunol 94 (1993) 174-181
5. Van den Brande J.M., Braat H., van den Brink G.R., et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology 124 (2003) 1774-1785
6. Lugering A., Schmidt M., Lugering N., et al. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. Gastroenterology 121 (2001) 1145-1157
7. ten Hove T., van Montfrans C., Peppelenbosch M.P., et al. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut 50 (2002) 206-211
8. Ringheam M., Markowitz J., Chawla A., et al. Effects of infliximab on apoptosis and reverse signalling of monocytes. Gastroenterology 124 (2003) A101
9. Shen C., Maerten P., Geboes K., et al. Infliximab induces apoptosis of monocytes and T lymphocytes in a human-mouse chimeric model. Clin Immunol 115 (2005) 250-259
10. Shen C., Assche G.V., Colpaert S., et al. Adalimumab induces apoptosis of human monocytes: a comparative study with infliximab and etanercept. Aliment Pharmacol Ther 21 (2005) 251-258
11. Shen C., Van Assche G., Rutgeerts P., et al. Caspase activation and apoptosis induction by adalimumab: demonstration in vitro and in vivo in a chimeric mouse model. Inflamm Bowel Dis 12 (2006) 22-28
12. Ina K., Itoh J., Fukushima K., et al. Resistance of Crohn's disease T cells to multiple apoptotic signals is associated with a Bcl-2/Bax mucosal imbalance. J Immunol 163 (1999) 1081-1090
13. Nesbitt A., Fossati G., Bergin M., et al. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents. Inflamm Bowel Dis 13 (2007) 1323-1332
14. Stefanelli T., Malesci A., De La Rue S.A., et al. Anti-adhesion molecule therapies in inflammatory bowel disease: touch and go. Autoimmun Rev 7 (2008) 364-369
15. Keane J., Gershon S., Wise R.P., et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345 (2001) 1098-1104
16. Toruner M., Loftus Jr. E.V., Harmsen W.S., et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 134 4 (2008 Apr) 929-936
17. Sandborn W., Rutgeerts P., Reinisch W., et al. A randomized, double-blind, controlled trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy: the SONIC trial. Am J Gastroenterol 103 Suppl 1 (2008) Abstract 1117
18. Rutgeerts P., Sandborn W.J., Feagan B.G., et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 353 23 (2005 Dec 8) 2462-2476
19. Regueiro M., Valentine J., Plevy S., et al. Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel disease. Am J Gastroenterol 98 (2003) 1821-1826
20. Joseph A., Raj D., Dua H.S., et al. Infliximab in the treatment of refractory posterior uveitis. Ophthalmology 110 (2003) 1449-1453
21. Van den Bosch F., Kruithof E., De Vos M., et al. Crohn's disease associated with spondyloarthropathy: effect of TNF-alpha blockade with infliximab on articular symptoms. Lancet 356 (2000) 1821-1822
22. Braun J., Brandt J., Listing J., et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 359 (2002) 1187-1193
23. Gorman J.D., Sack K.E., and Davis Jr. J.C. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med 346 (2002) 1349-1356
24. Hanauer S., Wagner C., Bala M., et al. Incidence and importance of antibody responses to infliximab after maintenance of episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol 2 (2004) 542-553
25. Rutgeerts P., Feagan B.G., Lichtenstein G.R., et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 126 (2004) 402-413
26. Chung E.S., Packer M., Anti-TNF Therapy Against Congestive Heart Failure Investigators, et al. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF therapy against congestive heart failure (ATTACH) trial. Circulation 107 (2003) 3133-3140
27. Fidder H.H., Schnitzler F., Ferrante M., et al. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single center cohort study. Gut 2 (2008 Oct) (Epub ahead of print)
28. Stübgen J.P. Tumor necrosis factor-alpha antagonists and neuropathy. Muscle Nerve 37 (2008) 281-292
29. Vermeire S., Noman M., Van Assche G., et al. Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort study. Gastroenterology 125 (2003) 32-39
30. Beaugerie L., Carrat F., Bouvier A.-M., et al. Excess risk of lymphoproliferative disorders (LPD) in inflammatory bowel diseases (IBD): interim results of the CESAME cohort. Gastroenterology 134 Suppl 1 (2008) A116-A117
31. Kandiel A., Fraser A.G., Korelitz B.I., et al. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 54 (2005) 1121-1125
32. Mackey A.C., Green L., Liang L.C., et al. Hepatosplenic T-cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr 44 (2007) 265-267
33. US Food and Drug Administration. Center for Drug Evaluation and Research website. Available at:. [accessed 13.07.08]
34. Langer-Gould A., Atlas S.W., Green A.J., et al. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 353 (2005) 375-381
35. Kleinschmidt-DeMasters B.K., and Tyler K.L. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 353 (2005) 369-374
36. Van Assche G., Van Ranst M., Sciot R., et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med 353 (2005) 362-368
37. Yousry T.A., Major E.O., Ryschkewitsch C., et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 354 (2006) 924-933
38. Hwang W.Y., and Foote J. Immunogenicity of engineered antibodies. Methods 36 (2005) 3-10
39. Cheifetz A., Smedley M., Martin S., et al. The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol 98 (2003) 1315-1324
40. Lamireau T., Cezard J.P., French-Speaking Group for Pediatric Gastroenterology Nutrition, et al. Efficacy and tolerance of infliximab in children and adolescents with Crohn's disease. Inflamm Bowel Dis 10 (2004) 745-750
41. Seiderer J., Goke B., and Ochsenkuhn T. Safety aspects of infliximab in inflammatory bowel disease patients. A retrospective cohort study in 100 patients of a German University Hospital. Digestion 70 (2004) 3-9
42. Colombel J.F., Loftus Jr. E.V., Tremaine W.J., et al. The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology 126 (2004) 19-31
43. Cheifetz A., Smedley M., Martin S., et al. The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol 98 (2003) 1315-1324
44. Kugathasan S., Levy M.B., Saeian K., et al. Infliximab retreatment in adults and children with Crohn's disease: risk factors for the development of delayed severe systemic reaction. Am J Gastroenterol 97 (2002) 1408-1414
45. Baert F., Noman M., Vermeire S., et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 348 (2003) 601-608
46. Louis E., Rutgeerts P., Westhovens R., et al. Short and long term safety of remicade (infliximab) in Crohn's disease and rheumatoid arthritis. Gastroenterology 122 (2002) W1347
47. Miele E., Markowitz J.E., Mamula P., et al. Human antichimeric antibody in children and young adults with inflammatory bowel disease receiving infliximab. J Pediatr Gastroenterol Nutr 38 (2004) 502-508
48. Crandall W.V., and Mackner L.M. Infusion reactions to infliximab in children and adolescents: frequency, outcome and a predictive model. Aliment Pharmacol Ther 17 (2003) 75-84
49. Farrell R.J., Alsahli M., Jeen Y.T., et al. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. Gastroenterology 124 (2003) 917-924
50. Vermeire S., Noman M., Van Assche G., et al. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. Gut 56 (2007) 1226-1231
51. Van Assche G., Magdelaine-Beuzelin C., D'Haens G., et al. Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology 134 (2008) 1861-1868
52. Colombel J.F., Sandborn W.J., Rutgeerts P., et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 132 (2007) 52-65
53. Baert F., De Vos M., Belgian IBD Research Group, et al. Immunogenicity of infliximab: how to handle the problem?. Acta Gastroenterol Belg 70 (2007) 163-170